PepGen Q1 2023 net loss $16.3M; cash $165.4M; pipeline milestones on track

PepGen Inc.

2023-Q1 EPS reported -$0.69

Net loss of $16.3M for Q1 2023 vs $18.2M in Q1 2022; R&D expense $14.4M, G&A $3.7M.
Cash, cash equivalents, and investments of $165.4M as of March 31, 2023; runway into early 2025.
Phase 2 CONNECT1-EDO51 (open-label) for DMD expected to start in Canada H1 2023.
Phase 2 CONNECT2-EDO51 (randomized, placebo-controlled) multinational study expected H2 2023.
Phase 1 FREEDOM-DM1 for myotonic dystrophy type 1 expected to start H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PepGen Inc. reported the quarter ended March 31, 2023 results: net income $16.3 million.

Period: the quarter ended March 31, 2023
Net income: $16.3 million
Result: reported results

Exact text from the filing

Net loss was $16.3 million for the three months ended March 31, 2023, compared to $18.2 million for the same period in 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

PepGen Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020826

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.